Clinical trial · Observational
Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents
Evaluation of the Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents
NCT01947296CI-TRIAL-00026123CHIMORALcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose is to estimate evolution of patients treated by oral neoplastic agents, in term of early or unforeseen recourse to the hospital for adverse events.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Group " coordinated care"
- description
- Patient living in place covered by cancer network participating to the study is in the group "coordinated care"
- label
- Group " usual care "
- description
- Patient living in place covered by cancer network non participating to the study or without cancer network is in the group "usual care"
Primary outcomes (1)
- measure
- Number of early or unforeseen recourses to hospital for adverse event.
- timeFrame
- within the first 6 monts after oral neoplastic agent introduction
Secondary outcomes (11)
- measure
- all deaths and deaths from AE
- timeFrame
- within the first 6 monts after oral neoplastic agent introduction
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients affected by cancer (breast, colorectal, liver, lung, kidney, gastrointestinal stromal tumor, pancreas) * treated by capecitabine, erlotinib, gefitinib, imatinib, lapatinib, sorafenib, sunitinib, vinorelbine, Evérolimus, Pazopanib, Etoposide, Topotécan * 18 years old or more Exclusion Criteria: * refusal to participate * lack proficiency in French , * having a Performance Status \> 2, * home based care, * patient enrolled in clinical trials * patient enrolled in therapeutic education program * patient under administrative supervision or legal guardianship * not affiliated with Patient Social Security or CMU (recipient or beneficiary)
References
Publications (0)
Data not yet available
No reference posted for this study.